WAKIX Logo
Back

Terms of Use

Last updated: October, 2019

Harmony Biosciences, LLC ("Harmony") has provided this website and its content for general informational purposes only, for US residents. Harmony will undertake reasonable efforts to ensure that all information added to this site is accurate at the time such content is made available. Please note, however, that Harmony makes no warranties or representations that the information is accurate and accepts no liability for any errors or omissions in the content of the site or any losses or damage that may arise from relying on this information. The information may be changed by Harmony at any time.

We encourage you to read these Terms of Use in their entirety before using the site. By accessing and using the site or its services, you agree to these Terms of Use and to the collection and use of information in accordance with our Privacy Policy, without limitation or qualification.

Use of Materials and Intellectual Property Rights
This site and its services contain content specifically provided by Harmony or its partners. Such content is protected by copyrights, trademarks, and/or other proprietary rights and laws. Users of this site shall abide by all copyright notices, information, and restrictions contained in any such content. The user shall not sell, license, rent, modify, distribute, copy, reproduce, transmit, publicly display, publicly perform, publish, adapt, edit, create derivative works from, or otherwise exploit any content or third-party submissions or other proprietary rights not owned by the user, (i) without the consent of the respective owners or other valid right, and (ii) in any way that violates any third-party right.

Harmony authorizes you to copy materials published on this website for noncommercial use only, provided that any copy of these materials which you make retains all copyright and other proprietary notices.

Links to and From Third-Party Websites
The website may from time to time contain in-text links to third-party websites, and third-party websites may provide links to this site. Harmony is not responsible for, and accepts no liability in respect of, any information or opinion contained on any third-party site. As Harmony has no control over such sites and because their content is subject to change without notice to Harmony, it is the responsibility of the user of the site to ensure that any information accessed is accurate and that software which is downloaded from that site is free of viruses or any other items of a destructive nature. Harmony accepts no liability whatsoever in respect of any loss, damage, costs or liability incurred through any such downloaded material.

Information Does Not Substitute for Care by a Health Professional
The information on the site is intended only to provide knowledge of disease information. This information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other healthcare provider. Harmony does not recommend the self-management of health problems. Should you have any healthcare-related questions, please call or see your physician or other healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here. Information is not necessarily accurate, complete, or current.

Information accessed on the website is not exhaustive. Harmony makes reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations as to its accuracy or completeness. This information is provided "as is" without warranty of any kind, either express or implied, including but not limited to implied warranty of fitness for a particular purpose. Harmony is not responsible for computer damage resulting from using the website.

Site Access
Harmony makes no representation or warranty that access to the website will be available on a timely basis, will be uninterrupted, or will be error-free. Harmony does not warrant that these pages, or the server that makes them available, are free of viruses or other harmful elements. In no event shall Harmony, its affiliates and subsidiaries, and their respective officers, directors, employees, agents, representatives, information providers, and licensors and their respective heirs and assigns, be liable for any direct, indirect, incidental, consequential, exemplary, special, punitive, or other damages even if informed of the possibility of such damages. The above exclusion may not apply in jurisdictions to the extent that they do not allow the exclusion of implied warranties. Any personally identifiable information in electronic communications to this website is governed by Harmony’s Privacy Policy. Harmony shall be free to use or copy all other information in any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purposes, including disclosure to third parties and/or developing, manufacturing and/or marketing products or services.

Changes to Terms of Use
Harmony may modify these Terms of Use at any time without notice. Harmony may terminate these Terms of Use, terminate user access to all or any part of this site or any content or any service, or suspend any individual user’s access to all or any part of this site or any content or any service, at any time, without notice, if we believe in our sole judgment that the user has breached or may breach any term or condition of this agreement, or for our convenience. The user may terminate these Terms of Use at any time by destroying all materials received from this site (including content) and ceasing to use this site and its content and services. Harmony reserves the right to remove any content or services from the site at any time.

Agreement to Terms of Use
By accessing and using the site or its services, you agree to these Terms of Use and to the collection and use of information in accordance with our Privacy Policy, without limitation or qualification. Except as expressly provided in a particular "legal notice" on this site, these Terms of Use constitute the entire agreement between the user and Harmony with respect to the use of this site and its content and services.

All materials and information appearing on this site are intended for US residents only. These Terms of Use were last updated: October 2019.

Back

INDICATIONS AND USAGE & IMPORTANT SAFETY INFORMATION

  • WAKIX® (pitolisant) is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

IMPORTANT SAFETY INFORMATION

Contraindications

  • WAKIX is contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

  • WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
  • The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

  • In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

  • Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
  • Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
  • H receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H receptor antagonists.
  • WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

  • WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.
  • The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
  • WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
  • WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
  • Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

Please see the Full Prescribing Information for WAKIX.

To report suspected adverse reactions, contact Harmony Biosciences, LLC at 1-800-833-7460 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.